Please login to the form below

Not currently logged in


This page shows the latest PRINCIPLE study news and features for those working in and with pharma, biotech and healthcare.

AZ’s Farxiga has no significant benefit for hospitalised COVID-19 patients

AZ’s Farxiga has no significant benefit for hospitalised COVID-19 patients

Results from this study showed that 11.2% of hospitalised COVID-19 patients who received Farxiga experienced an organ failure or died after 30 days of treatment versus 13.8% in ... reasonable doubt because patient outcomes rapidly improved during the

Latest news

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Virtual meeting technologies for reducing emissions and waste in the healthcare industry
Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...